Tuesday, October 23, 2012

Rep. Markey Letter To Department of Justice to Investigate New England Compounding Center, and to Probe into DEA’s Past Oversight of Pharmaceutical Compounding

On October 22, 2012, the FDA Blog has a post written by By Karla L. Palmer & Larry K. Houck, which addresses Representative Markey's Letter to the Department of Justice as it relates to the DEA.  The blog post provides in part:
The letter notes that almost 1,000 specific formulations of recalled NECC drug products contain controlled substances such as cocaine, morphine, hydromorphone, meperidine, sufentanil, fentanyl and ketamine. (All of these substances are schedule II substances except for ketamine, which is a schedule III substance).

No comments: